Story

Vusion Group Shares Plunge After AlphaValue Initiates 'Sell' Rating

ENTHMSVIIDZHZH-TWJAKOHI
Jul 15, 20261 min read
Vusion Group Shares Plunge After AlphaValue Initiates 'Sell' Rating

Summary

Shares of Vusion Group fell nearly 8% on Monday after brokerage AlphaValue initiated coverage with a 'sell' rating, citing significant risks related to the company's business model and its heavy reliance on a contract with Walmart.

Text size
Background

Vusion Group (EPA:VU) shares experienced a sharp decline of nearly 8% on Monday following a new research report from AlphaValue. The brokerage initiated its coverage of the electronic shelf-labeling company with a "sell" rating, flagging what it described as severe cash and revenue risks.

Analyst Cites 'Optical Illusion'

In its initiation note, AlphaValue expressed skepticism about Vusion's strategic shift toward software-based Value Added Services (VAS). The brokerage called the new business model an "optical illusion," questioning its financial substance.

AlphaValue's analysis claimed the VAS segment lacks IFRS substance, has no clear cost allocation, and operates on an implied 100% gross margin. The firm argued that these accounting practices may be masking underlying profitability issues within the company's core operations.

Sample IUX Markets – In-articleAd

Walmart Contract Under Scrutiny

Further concerns were raised regarding Vusion's significant customer concentration. AlphaValue highlighted the company's heavy dependence on a major contract with U.S. retail giant Walmart (NYSE:WMT), which it estimates will account for over 70% of Vusion's revenue in 2025.

The report noted that this pivotal contract is set to end in 2026 and characterized it as having "thin economics" and being a source of "heavy cash consumption" for Vusion. The brokerage projects that Vusion will struggle to replace the sales volume from Walmart, placing the company's ambitious 2027 financial targets out of reach.

Read next

More on Stocks
Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO

Stocks

Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO

Sep 20, 2026

Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ) has resubmitted its application for a main board listing on the Hong Kong Stock Exchange, aiming to secure a dual listing to access international capital. The company specializes in drugs for central nervous system and cardiovascular diseases.

Back to latest news

LATEST